L-BLP25 vaccine plus letrozole for breast cancer

Is translation possible?

Michael DeGregorio, Gregory T. Wurz, Audrey Gutierrez, Michael Wolf

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have recently reported immunomodulatory effects for tamoxifen and letrozole on the L-BLP25 (Stimuvax@®)-induced immune response in a MUC1-expressing breast cancer mouse model. While neither tamoxifen nor letrozole appeared to interfere with the Th1-polarized cytokine response induced by L-BLP25, only letrozole increased the survival advantage of L-BLP25.

Original languageEnglish (US)
Pages (from-to)1422-1424
Number of pages3
JournalOncoImmunology
Volume1
Issue number8
DOIs
StatePublished - 2012

Fingerprint

letrozole
Vaccines
Tamoxifen
Breast Neoplasms
Cytokines
L-BLP25

Keywords

  • Breast cancer
  • L-BLP25
  • Letrozole
  • MMT model
  • Tamoxifen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

DeGregorio, M., Wurz, G. T., Gutierrez, A., & Wolf, M. (2012). L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible? OncoImmunology, 1(8), 1422-1424. https://doi.org/10.4161/onci.21129

L-BLP25 vaccine plus letrozole for breast cancer : Is translation possible? / DeGregorio, Michael; Wurz, Gregory T.; Gutierrez, Audrey; Wolf, Michael.

In: OncoImmunology, Vol. 1, No. 8, 2012, p. 1422-1424.

Research output: Contribution to journalArticle

DeGregorio, M, Wurz, GT, Gutierrez, A & Wolf, M 2012, 'L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?', OncoImmunology, vol. 1, no. 8, pp. 1422-1424. https://doi.org/10.4161/onci.21129
DeGregorio, Michael ; Wurz, Gregory T. ; Gutierrez, Audrey ; Wolf, Michael. / L-BLP25 vaccine plus letrozole for breast cancer : Is translation possible?. In: OncoImmunology. 2012 ; Vol. 1, No. 8. pp. 1422-1424.
@article{ef67a2490b2d4307876f54eb20f3abec,
title = "L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?",
abstract = "We have recently reported immunomodulatory effects for tamoxifen and letrozole on the L-BLP25 (Stimuvax@{\circledR})-induced immune response in a MUC1-expressing breast cancer mouse model. While neither tamoxifen nor letrozole appeared to interfere with the Th1-polarized cytokine response induced by L-BLP25, only letrozole increased the survival advantage of L-BLP25.",
keywords = "Breast cancer, L-BLP25, Letrozole, MMT model, Tamoxifen",
author = "Michael DeGregorio and Wurz, {Gregory T.} and Audrey Gutierrez and Michael Wolf",
year = "2012",
doi = "10.4161/onci.21129",
language = "English (US)",
volume = "1",
pages = "1422--1424",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - L-BLP25 vaccine plus letrozole for breast cancer

T2 - Is translation possible?

AU - DeGregorio, Michael

AU - Wurz, Gregory T.

AU - Gutierrez, Audrey

AU - Wolf, Michael

PY - 2012

Y1 - 2012

N2 - We have recently reported immunomodulatory effects for tamoxifen and letrozole on the L-BLP25 (Stimuvax@®)-induced immune response in a MUC1-expressing breast cancer mouse model. While neither tamoxifen nor letrozole appeared to interfere with the Th1-polarized cytokine response induced by L-BLP25, only letrozole increased the survival advantage of L-BLP25.

AB - We have recently reported immunomodulatory effects for tamoxifen and letrozole on the L-BLP25 (Stimuvax@®)-induced immune response in a MUC1-expressing breast cancer mouse model. While neither tamoxifen nor letrozole appeared to interfere with the Th1-polarized cytokine response induced by L-BLP25, only letrozole increased the survival advantage of L-BLP25.

KW - Breast cancer

KW - L-BLP25

KW - Letrozole

KW - MMT model

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84875366067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875366067&partnerID=8YFLogxK

U2 - 10.4161/onci.21129

DO - 10.4161/onci.21129

M3 - Article

VL - 1

SP - 1422

EP - 1424

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

ER -